Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the development of antibody drug conjugates (ADC) for cancer patients with unmet need. The company develops XMT-1536, a Dolaflexin ADC targeting NaPi2b that is in Phase I clinical trial for the treatment of patients with ovarian cancer and non-small cell lung cancer (NSCLC) adenocarcinoma; and XMT-1592, a Dolasynthen ADC targeting NaPi2b-expressing tumors, which is in phase I clinical trial for the treatment of ovarian cancer and NSCLC adenocarcinoma. It also develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen development candidate. The company has a strategic research and development partnerships with Merck KGaA and Asana BioSciences, LLC for the development of ADC product candidates utilizing Fleximer. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc. was incorporated in 2001 and is headquartered in Cambridge, Massachusetts.
IPO Year: 2017
Exchange: NASDAQ
Website: mersana.com
Date | Price Target | Rating | Analyst |
---|---|---|---|
3/19/2024 | $5.00 | Underweight → Neutral | JP Morgan |
2/29/2024 | $6.00 | Neutral → Buy | BTIG Research |
2/29/2024 | $7.00 | Neutral → Buy | Guggenheim |
2/29/2024 | $2.00 → $7.00 | Neutral → Outperform | Wedbush |
12/4/2023 | $1.00 → $5.00 | Neutral → Buy | Citigroup |
7/28/2023 | $7.00 → $1.00 | Outperform → Neutral | Robert W. Baird |
7/27/2023 | Neutral → Underweight | JP Morgan | |
7/27/2023 | Buy → Neutral | Citigroup | |
7/27/2023 | Buy → Neutral | BTIG Research | |
7/27/2023 | Buy → Neutral | Guggenheim |
4 - Mersana Therapeutics, Inc. (0001442836) (Issuer)
4 - Mersana Therapeutics, Inc. (0001442836) (Issuer)
4 - Mersana Therapeutics, Inc. (0001442836) (Issuer)
4 - Mersana Therapeutics, Inc. (0001442836) (Issuer)
4 - Mersana Therapeutics, Inc. (0001442836) (Issuer)
4 - Mersana Therapeutics, Inc. (0001442836) (Issuer)
4 - Mersana Therapeutics, Inc. (0001442836) (Issuer)
4 - Mersana Therapeutics, Inc. (0001442836) (Issuer)
4 - Mersana Therapeutics, Inc. (0001442836) (Issuer)
4/A - Mersana Therapeutics, Inc. (0001442836) (Issuer)
10-Q - Mersana Therapeutics, Inc. (0001442836) (Filer)
8-K - Mersana Therapeutics, Inc. (0001442836) (Filer)
8-K - Mersana Therapeutics, Inc. (0001442836) (Filer)
EFFECT - Mersana Therapeutics, Inc. (0001442836) (Filer)
424B5 - Mersana Therapeutics, Inc. (0001442836) (Filer)
10-Q - Mersana Therapeutics, Inc. (0001442836) (Filer)
8-K - Mersana Therapeutics, Inc. (0001442836) (Filer)
ARS - Mersana Therapeutics, Inc. (0001442836) (Filer)
DEF 14A - Mersana Therapeutics, Inc. (0001442836) (Filer)
DEFA14A - Mersana Therapeutics, Inc. (0001442836) (Filer)
Dose escalation advancing in Phase 1 clinical trials of both XMT-1660 and XMT-2056 Continue to expect to announce initial XMT-1660 clinical data and initiate expansion in the second half of 2024 Capital resources expected to support current operating plan commitments into 2026 Conference call today at 8:00 a.m. ET CAMBRIDGE, Mass., Aug. 13, 2024 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today provided a business update and reported financial results for the second quarter
CAMBRIDGE, Mass., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that it will provide business updates and report its financial results for the second quarter ended June 30, 2024 on Tuesday, August 13, 2024. The company will host a conference call and webcast at 8:00 a.m. Eastern Time that morning. To access the call, please dial 833-255-2826 (domestic) or 412-317-0689 (international). A live webcast of the presentation will be available on the Investors & Media sec
CAMBRIDGE, Mass., May 22, 2024 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that members of management will present at the following upcoming investor conferences: TD Cowen 5th Annual Oncology Innovation SummitFormat: Fireside chatDate/Time: Wednesday, May 29, 2024, at 9:00 a.m. Eastern TimeGoldman Sachs 45th Annual Global Healthcare ConferenceFormat: Fireside chatDate/Time: Wednesday, June 12, 2024, at 8:00 a.m. Eastern Time Live webcasts of thes
Maximum tolerated dose not yet established in Phase 1 clinical trial of XMT-1660; enrollment in dose escalation and backfill cohorts continuing in parallel; expect to announce initial clinical data and initiate expansion in the second half of 2024Patient recruitment ongoing in Phase 1 clinical trial of XMT-2056; plan to advance dose escalation in 2024 Continue to expect capital resources will support current operating plan commitments into 2026Conference call today at 8:00 a.m. ET CAMBRIDGE, Mass., May 09, 2024 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugate
CAMBRIDGE, Mass., May 03, 2024 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that on May 1, 2024, an authorized sub-committee of the Board of Directors of Mersana granted an inducement award, consisting of a restricted stock unit (RSU) award to acquire 35,100 shares of its common stock, to one new employee whose employment commenced in April 2024. The award was granted as an inducement material to the new employee entering employment with Mersana in accordance with Nasdaq Listing
CAMBRIDGE, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that it will provide business updates and report its financial results for the first quarter ended March 31, 2024 on Thursday, May 9, 2024. The company will host a conference call and webcast at 8:00 a.m. Eastern Time that morning. To access the call, please dial 833-255-2826 (domestic) or 412-317-0689 (international). A live webcast of the presentation will be available on the Investors & Media section
CAMBRIDGE, Mass., April 04, 2024 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that on April 1, 2024, an authorized sub-committee of the Board of Directors of Mersana granted an inducement award, consisting of a restricted stock unit (RSU) award to acquire 35,100 shares of its common stock, to one new employee whose employment commenced in March 2024. The award was granted as an inducement material to the new employee entering employment with Mersana in accordance with Nasdaq Lis
Enrollment in dose escalation and backfill cohorts continuing in Phase 1 clinical trial of XMT-1660; expect to initiate tumor-specific expansion cohorts in the second quarter of 2024 and announce initial clinical data in mid-2024Phase 1 clinical trial of XMT-2056 restarting; plan to advance dose escalation in 2024 Continue to expect capital resources will support current operating plan commitments into 2026Conference call today at 8:00 a.m. ET CAMBRIDGE, Mass., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas
CAMBRIDGE, Mass., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that members of management will present at the following upcoming investor conferences: TD Cowen 44th Annual Health Care Conference Format:Panel discussionDate/Time:Tuesday, March 5, 2024, at 9:10 a.m. Eastern Time Leerink Global Biopharma Conference Format:Fireside chatDate/Time:Tuesday, March 12, 2024, at 8:40 a.m. Eastern Time Live webcasts of these events will be available on the Investors & Media
CAMBRIDGE, Mass., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that it will provide business updates and report its financial results for the fourth quarter and full year ended December 31, 2023 on Wednesday, February 28, 2024. The company will host a conference call and webcast at 8:00 a.m. Eastern Time that morning. To access the call, please dial 877-270-2148 (domestic) or 412-902-6510 (international). A live webcast of the presentation will be available on the
SC 13G - Mersana Therapeutics, Inc. (0001442836) (Subject)
SC 13G/A - Mersana Therapeutics, Inc. (0001442836) (Subject)
SC 13G - Mersana Therapeutics, Inc. (0001442836) (Subject)
SC 13G/A - Mersana Therapeutics, Inc. (0001442836) (Subject)
SC 13G/A - Mersana Therapeutics, Inc. (0001442836) (Subject)
SC 13G - Mersana Therapeutics, Inc. (0001442836) (Subject)
SC 13G - Mersana Therapeutics, Inc. (0001442836) (Subject)
SC 13G/A - Mersana Therapeutics, Inc. (0001442836) (Subject)
SC 13G/A - Mersana Therapeutics, Inc. (0001442836) (Subject)
SC 13G - Mersana Therapeutics, Inc. (0001442836) (Subject)
Anna Protopapas to retire as President and Chief Executive Officer (CEO); will remain a member of the Board of DirectorsMartin Huber, M.D., current member of the Board of Directors, to be named President and CEOBrian DeSchuytner named Chief Operating Officer; Mohan Bala, Ph.D., named Chief Development Officer CAMBRIDGE, Mass., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced the retirement of Anna Protopapas, President and CEO, effective September 10, 2023, and the
CAMBRIDGE, Mass., March 10, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today provided an update about its capital resources. A de minimis amount of Mersana's capital is currently held in a checking account at Silicon Valley Bank (SVB). The balance of the company's capital resources is held in a custodial account managed by another institution and in money market funds of institutions other than SVB. Mersana has a loan and security agreement with Oxford Finance LLC and SVB. As previously
CAMBRIDGE, Mass., Oct. 25, 2021 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced the appointment of Mohan Bala, Ph.D., as SVP, Strategic Product Planning & Program Leadership, effective Monday, October 25, 2021. Dr. Bala will assume strategic product planning responsibilities from Brian DeSchuytner who has been named SVP and Chief Financial Officer. Mr. DeSchuytner will continue to lead finance, business development, corporate strategy and investor relations and remain Mersana's pri
CAMBRIDGE, Mass., Aug. 16, 2021 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced the appointment of Tushar Misra, Ph.D., as Chief Manufacturing Officer, effective Monday, August 16, 2021. Dr. Misra replaces Michael Kaufman, Ph.D., who is retiring from Mersana after more than five years with the Company. Dr. Kaufman will remain at Mersana to ensure a smooth transition until September 10, 2021. "Tushar is a seasoned biopharmaceutical executive with a track record in the scale up of m
CAMBRIDGE, Mass., April 26, 2021 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced the appointment of Alejandra Carvajal as Senior Vice President and Chief Legal Officer. "With our UPLIFT strategy now underway for UpRi and our growing pipeline of product candidates derived from our innovative ADC platforms, we are thrilled to have Alejandra join the team at this time of immense growth," said Anna Protopapas, President and Chief Executive Officer of Mersana Therapeutics. "Alejandra's
CAMBRIDGE, Mass., March 11, 2021 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (Nasdaq: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced the appointment of Allene Diaz to its board of directors. “Allene’s breadth of knowledge in strategic product planning, portfolio management and commercialization of cancer therapeutics will be invaluable to Mersana as we focus on building UpRi as a foundational therapy for the treatment of ovarian cancer and building out our maturing pipeline of ADC candidates. With our growing portfolio of pr
CAMBRIDGE, Mass., Dec. 02, 2020 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (Nasdaq: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced the grant of an inducement award to the newly appointed Senior Vice President and Chief Medical Officer, Arvin Yang, M.D., Ph.D. In connection with the appointment, the Compensation Committee of the Board of Directors of Mersana Therapeutics approved a stock option grant to Dr. Yang as an inducement material to Dr. Yang’s entering into employment with Mersana Therapeutics, in accordance with Nasdaq Lis
Mersana Therapeutics (NASDAQ:MRSN) reported quarterly losses of $(0.16) per share which beat the analyst consensus estimate of $(0.19) by 15.79 percent. The company reported quarterly sales of $9.245 million which beat the analyst consensus estimate of $8.500 million by 8.76 percent. This is a 18.50 percent increase over sales of $7.802 million the same period last year.
Shares of Teledyne Technologies Incorporated (NYSE:TDY) fell sharply during Wednesday's session after the company reported worse-than-expected first-quarter financial results and cut FY24 adjusted EPS guidance. Teledyne Technologies posted adjusted earnings of $4.55 per share, missing market estimates of $4.63 per share. The company's quarterly sales came in at $1.35 billion versus expectations of $1.40 billion, according to data from Benzinga Pro. Teledyne Technologies shares dipped 9.3% to $369.16 on Wednesday. Here are some other stocks moving in today’s mid-day session. Gainers Chicken Soup for the Soul Entertainment, Inc. (NASDAQ:CSSE) gained 136% to $0.3570. BranchOu
5 analysts have shared their evaluations of Mersana Therapeutics (NASDAQ:MRSN) during the recent three months, expressing a mix of bullish and bearish perspectives. The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 2 1 2 0 0 Last 30D 0 0 1 0 0 1M Ago 2 1 1 0 0 2M Ago 0 0 0 0 0 3M Ago 0 0 0 0 0 Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $6.6, a high estimate of $9.00, and a low estimate of $5.00. Witnessing a
JP Morgan analyst Brian Cheng upgrades Mersana Therapeutics (NASDAQ:MRSN) from Underweight to Neutral and announces $5 price target.
Gainers Cue Health (NASDAQ:HLTH) shares increased by 12.1% to $0.22 during Friday's after-market session. The company's market cap stands at $34.8 million. As per the press release, Q4 earnings came out 2 days ago. Aclarion (NASDAQ:ACON) shares increased by 10.39% to $0.44. The market value of their outstanding shares is at $3.1 million. BioSig Technologies (NASDAQ:BSGM) shares increased by 9.39% to $0.58. The market value of their outstanding shares is at $5.4 million. OptiNose (NASDAQ:OPTN) stock increased by 9.09% to $2.04. The company's market cap stands at $229.8 million. SCWorx (NASDAQ:WORX) stock rose 7.55% to $1.85. The market value of their outstanding shares is at $2.2 million
Shares of Butterfly Network, Inc. (NASDAQ:BFLY) fell sharply during Thursday’s session after the company reported mixed fourth-quarter financial results. Butterfly Network posted GAAP loss of 21 cents per share versus market estimates for a loss of 14 cents per share. The company’s quarterly sales came in at sales came in $16.52 million versus estimates of $15.35 million. Butterfly Network shares dipped 21.7% to $1.1588 on Thursday. Here are some other stocks moving in today's mid-day session. Gainers Enveric Biosciences, Inc. (NASDAQ:ENVB) gained 177.1% to $2.30 after the company announced it has signed three non-binding term sheets with an undisclosed biotechnology company to purs
U.S. stocks were higher, with the Nasdaq Composite gaining around 50 points on Thursday. Shares of Hormel Foods Corporation (NYSE:HRL) rose sharply during Thursday’s session after the company reported better-than-expected first-quarter earnings and reaffirmed FY24 outlook. The company reported first-quarter adjusted earnings per share of 41 cents, beating the analyst consensus of 34 cents. Quarterly revenues of $2.997 billion, beating the analyst consensus of $2.917 billion. Hormel Foods shares climbed 12.6% to $34.72 on Thursday. Here are some other big stocks recording gains in today’s session. Vertex, Inc. (NASDAQ:VERX) jumped 29.8% to $32.97 after the company reported better-than
Ratings for Mersana Therapeutics (NASDAQ:MRSN) were provided by 5 analysts in the past three months, showcasing a mix of bullish and bearish perspectives. The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 3 1 1 0 0 Last 30D 2 1 1 0 0 1M Ago 0 0 0 0 0 2M Ago 0 0 0 0 0 3M Ago 1 0 0 0 0 In the assessment of 12-month price targets, analysts unveil insights for Mersana Therapeutics, presenting an average target of $6.6, a high estimate of $9.00, and a low estimate of $5.00. This upward trend
JP Morgan upgraded Mersana Therapeutics from Underweight to Neutral and set a new price target of $5.00
BTIG Research upgraded Mersana Therapeutics from Neutral to Buy and set a new price target of $6.00
Guggenheim upgraded Mersana Therapeutics from Neutral to Buy and set a new price target of $7.00
Wedbush upgraded Mersana Therapeutics from Neutral to Outperform and set a new price target of $7.00 from $2.00 previously
Citigroup upgraded Mersana Therapeutics from Neutral to Buy and set a new price target of $5.00 from $1.00 previously
Robert W. Baird downgraded Mersana Therapeutics from Outperform to Neutral and set a new price target of $1.00 from $7.00 previously
JP Morgan downgraded Mersana Therapeutics from Neutral to Underweight
Citigroup downgraded Mersana Therapeutics from Buy to Neutral
BTIG Research downgraded Mersana Therapeutics from Buy to Neutral
Guggenheim downgraded Mersana Therapeutics from Buy to Neutral
Dose escalation advancing in Phase 1 clinical trials of both XMT-1660 and XMT-2056 Continue to expect to announce initial XMT-1660 clinical data and initiate expansion in the second half of 2024 Capital resources expected to support current operating plan commitments into 2026 Conference call today at 8:00 a.m. ET CAMBRIDGE, Mass., Aug. 13, 2024 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today provided a business update and reported financial results for the second quarter
CAMBRIDGE, Mass., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that it will provide business updates and report its financial results for the second quarter ended June 30, 2024 on Tuesday, August 13, 2024. The company will host a conference call and webcast at 8:00 a.m. Eastern Time that morning. To access the call, please dial 833-255-2826 (domestic) or 412-317-0689 (international). A live webcast of the presentation will be available on the Investors & Media sec
Maximum tolerated dose not yet established in Phase 1 clinical trial of XMT-1660; enrollment in dose escalation and backfill cohorts continuing in parallel; expect to announce initial clinical data and initiate expansion in the second half of 2024Patient recruitment ongoing in Phase 1 clinical trial of XMT-2056; plan to advance dose escalation in 2024 Continue to expect capital resources will support current operating plan commitments into 2026Conference call today at 8:00 a.m. ET CAMBRIDGE, Mass., May 09, 2024 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugate
CAMBRIDGE, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that it will provide business updates and report its financial results for the first quarter ended March 31, 2024 on Thursday, May 9, 2024. The company will host a conference call and webcast at 8:00 a.m. Eastern Time that morning. To access the call, please dial 833-255-2826 (domestic) or 412-317-0689 (international). A live webcast of the presentation will be available on the Investors & Media section
Enrollment in dose escalation and backfill cohorts continuing in Phase 1 clinical trial of XMT-1660; expect to initiate tumor-specific expansion cohorts in the second quarter of 2024 and announce initial clinical data in mid-2024Phase 1 clinical trial of XMT-2056 restarting; plan to advance dose escalation in 2024 Continue to expect capital resources will support current operating plan commitments into 2026Conference call today at 8:00 a.m. ET CAMBRIDGE, Mass., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas
CAMBRIDGE, Mass., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that it will provide business updates and report its financial results for the fourth quarter and full year ended December 31, 2023 on Wednesday, February 28, 2024. The company will host a conference call and webcast at 8:00 a.m. Eastern Time that morning. To access the call, please dial 877-270-2148 (domestic) or 412-902-6510 (international). A live webcast of the presentation will be available on the
Advancing dose escalation portion of Phase 1 clinical trial of XMT-1660, Mersana's B7-H4 Dolasynthen ADCPreparations underway to resume enrollment in Phase 1 clinical trial of XMT-2056, Mersana's HER2 Immunosynthen ADCCapital resources expected to support current operating plan commitments into 2026Conference call today at 8:00 a.m. ET CAMBRIDGE, Mass., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today provided a business update and reported financial results for the third quart
CAMBRIDGE, Mass., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that it will provide business updates and report its financial results for the third quarter ended September 30, 2023 on Tuesday, November 7, 2023. The company will host a conference call and webcast at 8:00 a.m. Eastern Time that morning. To access the call, please dial 877-270-2148 (domestic) or 412-902-6510 (international). A live webcast of the presentation will be available on the Investors & Medi
UPLIFT clinical trial did not meet its primary endpoint Company realigns focus and significantly reduces expenses to extend cash runway into 2026Conference call today at 8:00 a.m. ET CAMBRIDGE, Mass., July 27, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that the UPLIFT clinical trial of upifitamab rilsodotin (UpRi) did not meet its primary endpoint. UpRi is an ADC targeting the sodium-dependent phosphate transport protein NaPi2b and was developed utilizing the company's
Initiated dose expansion portion of UPGRADE-A clinical trial of UpRi in combination with carboplatin; interim data expected in second half of 2023Advanced enrollment in Phase 3 UP-NEXT clinical trial of UpRi and Phase 1 clinical trial of XMT-1660Plan to report topline data from UPLIFT registrational trial in mid-2023; potential Biologics License Application (BLA) submission anticipated around the end of 2023Capital resources expected to support operating plan commitments into the second half of 2024Conference call today at 8:00 a.m. ET CAMBRIDGE, Mass., May 09, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discover